Illumina vs SOLiD Which Is More Attractive?

Illumina and SOLiD are two of the leading companies in the field of genetic sequencing technologies, with both firms offering innovative solutions for researchers and healthcare professionals. Illumina has consistently been a market leader with its high-throughput sequencing systems, while SOLiD has carved out a niche with its unique sequencing chemistry. Investors interested in the genomics sector should consider the strengths and weaknesses of both companies, as well as market trends and competition, before making investment decisions in their respective stocks.

Illumina or SOLiD?

When comparing Illumina and SOLiD, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and SOLiD.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while SOLiD has a dividend yield of 1.08%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, SOLiD reports a 5-year dividend growth of 0.00% year and a payout ratio of 6.52%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -14.15 and SOLiD's P/E ratio at 6.07. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 10.56 while SOLiD's P/B ratio is 0.94.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while SOLiD's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -42.15% and SOLiD's ROE at 16.14%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $139.66 for Illumina and ₩4400.00 for SOLiD. Over the past year, Illumina's prices ranged from $97.36 to $156.66, with a yearly change of 60.90%. SOLiD's prices fluctuated between ₩4035.00 and ₩7370.00, with a yearly change of 82.65%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.